- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Onesource Specialty Pharma Ltd (ONEO)
Onesource Specialty Pharma Ltd stock price live, this page displays NSE ONEO stock exchange data. View the ONEO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Onesource Specialty Pharma Ltd real time stock price chart below.
What Is the Onesource Specialty Pharma Ltd Stock Price Today?
The Onesource Specialty Pharma Ltd stock price today is 1,619.70.
What Is the Stock Symbol for Onesource Specialty Pharma Ltd?
The stock symbol for Onesource Specialty Pharma Ltd is "ONEO."
What Stock Exchange Does Onesource Specialty Pharma Ltd Trade On?
Onesource Specialty Pharma Ltd is listed and trades on the NSE stock exchange.
Is Onesource Specialty Pharma Ltd a Good Stock to Buy?
Determining whether Onesource Specialty Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ONEO quote. (ISIN: INE013P01021)
What Is the Onesource Specialty Pharma Ltd Stock Price Today?
The Onesource Specialty Pharma Ltd stock price today is 1,619.70.
What Is the Stock Symbol for Onesource Specialty Pharma Ltd?
The stock symbol for Onesource Specialty Pharma Ltd is "ONEO."
What Stock Exchange Does Onesource Specialty Pharma Ltd Trade On?
Onesource Specialty Pharma Ltd is listed and trades on the NSE stock exchange.
Is Onesource Specialty Pharma Ltd a Good Stock to Buy?
Determining whether Onesource Specialty Pharma Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ONEO quote. (ISIN: INE013P01021)
1,619.70
-68.60(-4.06%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,601.50
1,692.90
52 wk Range
1,057.00
1,946.10
ONEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,601.501,692.90
52 wk Range
1,057.001,946.10
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
ONEO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
2,056.00
Upside
+26.94%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 2,056.00
(+26.94% Upside)
Onesource Specialty Pharma Ltd Earnings Call Summary for Q1/2027
- Q1 FY2027 revenue surged 37% YoY to INR 4,490M; EBITDA jumped 39% to INR 1,233M, driven by semaglutide launch and new customer contracts.
- Drug-device combination business leads growth; OneSource captures 40%+ of India's generic semaglutide pen market amid supply-constrained demand.
- Management reaffirmed FY2028 targets of INR 400M organic revenue and 40% EBITDA margin; biologics revenue expected from FY2029 onward.
- Capacity expansion underway: second cartridge line commercializing, third by end-FY2027, fourth in FY2028; injectable plant shutdown planned Q2-Q3.
- Shares flat at $1,653.90, down 0.02%; stock trades 61.7% above 52-week low but 18.4% below peak amid muted post-earnings reaction.
Last Updated: 2026-07-25, 09:32 a/m
Read Full TranscriptEarnings
Latest Release
Jul 24, 2026
EPS / Forecast
2.60 / --
Revenue / Forecast
4.49B / 4B
Compare ONEO to Peers and Sector
Metrics to compare | ONEO | Peers Peers - average of corresponding metrics from companies closely matching ONEO: PPLPHARMA, DCAL, SYNGENE, JUBLPHARMA, ANTHEM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONEOPeersSector |
|---|---|---|---|---|
P/E Ratio | −381.9x | 40.1x | −0.3x | |
PEG Ratio | 1.58 | 0.45 | 0.00 | |
Price/Book | 3.2x | 3.0x | 2.6x | |
Price / LTM Sales | 12.0x | 4.0x | 3.0x | |
Upside (Analyst Target) | 28.0% | 11.5% | 56.3% | |
Fair Value Upside | Unlock | 3.5% | 9.2% | Unlock |
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Onesource Specialty Pharma (ONEO) Stock Price Today?
The Onesource Specialty Pharma stock price today is 1,619.70 INR.
What Stock Exchange Does Onesource Specialty Pharma Trade On?
Onesource Specialty Pharma is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Onesource Specialty Pharma?
The stock symbol for Onesource Specialty Pharma is "ONEO."
What Is the Onesource Specialty Pharma Market Cap?
As of today, Onesource Specialty Pharma market cap is 185.69B INR.
What Is Onesource Specialty Pharma's Earnings Per Share (TTM)?
The Onesource Specialty Pharma EPS (TTM) is -4.05.
When Is the Next Onesource Specialty Pharma Earnings Date?
Onesource Specialty Pharma will release its next earnings report on Jul 27, 2026.
From a Technical Analysis Perspective, Is ONEO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Onesource Specialty Pharma Stock Split?
Onesource Specialty Pharma has split 0 times.
How Many Employees Does Onesource Specialty Pharma Have?
Onesource Specialty Pharma has 1412 employees.
What is the current trading status of Onesource Specialty Pharma (ONEO)?
As of Aug 02, 2026, Onesource Specialty Pharma (ONEO) is trading at a price of 1,619.70 INR, with a previous close of 1,688.30 INR. The stock has fluctuated within a day range of 1,601.50 INR to 1,692.90 INR, while its 52-week range spans from 1,057.00 INR to 1,946.10 INR.
What Is Onesource Specialty Pharma (ONEO) Price Target According to Analysts?
The average 12-month price target for Onesource Specialty Pharma is 2,056.00 INR, with a high estimate of 2400 INR and a low estimate of 1676 INR. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +26.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.